Results 11 to 20 of about 9,664,759 (367)
Clinical diagnosis of Alzheimer's disease [PDF]
Neurology, 1984 G. Mckhann +5 more
semanticscholar +2 more sources
Neuroinflammation in Alzheimer's disease [PDF]
The Lancet Neurology, 2015 Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release ...
M. Heneka +41 more
semanticscholar +12 more sources
Epigenetics of Alzheimer’s Disease [PDF]
Biomolecules, 2021 There are currently no validated biomarkers which can be used to accurately diagnose Alzheimer’s disease (AD) or to distinguish it from other dementia-causing neuropathologies. Moreover, to date, only symptomatic treatments exist for this progressive neurodegenerative disorder.
Matea Nikolac Perkovic +6 more
openaire +4 more sources
The Lancet, 2021 In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The most recent data indicate that, by 2050, the prevalence of dementia will double in Europe and triple worldwide, and that estimate is 3 times higher when based on a biological (rather than clinical) definition of Alzheimer's disease.
Scheltens, Philip +7 more
openaire +5 more sources
2023 Alzheimer's disease facts and figures
Alzheimer's & Dementia, 2023 This article describes the public health impact of Alzheimer's disease, including prevalence and incidence, mortality and morbidity, use and costs of care, and the overall impact on family caregivers, the dementia workforce and society.
semanticscholar +1 more source
Lecanemab in Early Alzheimer's Disease.
New England Journal of Medicine, 2022 BACKGROUND The accumulation of soluble and insoluble aggregated amyloid-beta (Aβ) may initiate or potentiate pathologic processes in Alzheimer's disease.
C. V. van Dyck +18 more
semanticscholar +1 more source
iScience, 2021 Summary: It has been suggested that aberrant activation of glycogen synthase kinase-3-beta (GSK-3β) can trigger abnormal tau hyperphosphorylation and aggregation, which ultimately leads to neuronal/synaptic damage and impaired cognition in Alzheimer ...
Ana Claudia Amaral +15 more
doaj +1 more source
Current Biology, 2018 The German psychiatrist and neuropathologist Alois Alzheimer was fascinated by the symptoms of Auguste D., a 50-year-old woman admitted to the Frankfurt Psychiatric Hospital in 1901 who suffered from memory disturbances, paranoia and progressive confusion. After her death and autopsy, Alzheimer described histological alterations in her brain that later
Grøntvedt, G. +5 more
openaire +5 more sources
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023 Introduction The study examined Black and White prospective participants’ views of barriers to and facilitators of participation in Alzheimer's disease (AD) biomarker research.
Johanne Eliacin +12 more
doaj +1 more source